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Abstract
Background: Although cisplatin is one of the most effective chemotherapeutic agents, cisplatin
alone does not achieve a satisfactory therapeutic outcome. Also cisplatin accumulation shows
toxicity to normal tissues. In this study, we examined the possibility of HemoHIM both to enhance
anticancer effect with cisplatin and to reduce the side effects of cisplatin in melanoma-bearing mice.
Methods: HemoHIM was prepared by adding the ethanol-insoluble fraction to the total water
extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix.
Anticancer effects of HemoHIM with cisplatin were evaluated in melanoma-bearing mice. We used
a Cr51-release assay to measure the activity of NK/Tc cell and ELISA to evaluate the production of
cytokines.
Results: In melanoma-bearing mice, cisplatin (4 mg/kg B.W.) reduced the size and weight of the
solid tumors, and HemoHIM supplementation with cisplatin enhanced the decrease of both the
tumor size (p < 0.1) and weight (p < 0.1). HemoHIM itself did not inhibit melanoma cell growth in
vitro, and did not disturb the effects of cisplatin in vitro. However HemoHIM administration
enhanced both NK cell and Tc cell activity in mice. Interestingly, HemoHIM increased the
proportion of NK cells in the spleen. In melanoma-bearing mice treated with cisplatin, HemoHIM
administration also increased the activity of NK cells and Tc cells and the IL-2 and IFN-γ secretion
from splenocytes, which seemed to contribute to the enhanced efficacy of cisplatin by HemoHIM.
Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.
Conclusion:  HemoHIM may be a beneficial supplement during cisplatin chemotherapy for
enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin.
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Background
Chemotherapy has been one of the major therapeutic
modalities commonly used for the treatment for a variety
of cancer patients. However, in many cases, chemotherapy
or radiotherapy alone cannot achieve a satisfactory thera-
peutic outcome, namely the complete remission of
tumors, and induces severe side effects at therapeutically
effective doses.
Cisplatin (cis-diaminedichloroplatinum (II) or CDDP), a
platinum-containing anticancer drug, is one of the most
commonly used cytotoxic agents for the treatment of a
variety of solid malignant tumors. Despite its excellent
anticancer activity, the clinical use of cisplatin is often lim-
ited by its undesirable side effects, such as severe nephro-
toxicity and hepatotoxicity [1,2]. Although the precise
mechanism for the cisplatin-induced toxicity is not well
understood, cisplatin is preferentially taken up and accu-
mulated in the liver and kidney cells [3], resulting in the
enhanced production of reactive oxygen species (ROS)
and the decrease in antioxidant enzymes [4-7]. Therefore,
antioxidants have been administered before cisplatin
treatment to protect against nephrotoxicity [8-10].
Complementary and alternative medicine defined by the
National Center as a group of diverse medical and health
care systems is not normally considered to be conven-
tional medicine [11]. Complementary and alternative
medicine does not inhibit tumor growth. These treat-
ments might be undertaken adjuvant to, or instead of,
conventional treatments. Numerous herbal medical prod-
ucts are promoted as complementary and alternative
medicines. In addition, scientific and medical studies in
Korea, China, and Japan, and more recently in the United
States, have increasingly shown that plant-derived
polysaccharides have potent immunotherapeutic proper-
ties with respect to the prevention and treatment of cancer
[12-19].
A new herbal composition, HemoHIM, was designed by
adding its polysaccharide fraction into a hot water extract
of an herb mixture consisting of Angelica Radix, Cnidium
Rhizoma and Paeonia Radix. This composition was
designed to protect the self-renewal tissues and to pro-
mote a recovery of the immune system against oxidative
stresses, such as irradiation [20,21]. The general composi-
tion of HemoHIM were 60.4% carbohydrate, 6% protein
and 33.6% other (Data not shown). The immune modu-
lating components in HemoHIM were the ethanol-insol-
uble fraction [21], and the polysaccharide content in this
fraction was 40.9% (± 3.8) (Data not shown). In addition,
the functional components included in the ethanol-solu-
ble fraction of HemoHIM were Gallic acid [0.2% (±
0.06)], chlorogenic acid [0.33% (± 0.05)], paeoniflorin
[1.32% (± 0.15)], nodakenin [0.58% (± 0.04)] and ben-
zoic acid [0.17% (± 0.05)] (Data not shown). Especially,
these 3 herbs are listed as raw materials in the Korea Food
Code. Finally, HemoHIM has been proven to be safe for
long-term administration (data not shown).
Surveillance capacity to tumor cells was mediated nonspe-
cifically by dendritic cells, macrophages and natural killer
cells and was mediated specifically by T cells including
cytotoxic T (Tc) cells. Both T and NK cells have been
shown to be anticancer effector cells [22,23]. Also, IFN-γ
and IL-2 have been shown to have anticancer activity in
animals [24,25].
In this study, the possibility of HemoHIM increasing the
immune surveillance capacity to tumor cells through both
NK cells and Tc cells in melanoma-bearing mice treated
with cisplatin was assessed. Also, we examined its protec-
tive effect against cisplatin-induced nephrotoxicity in
melanoma-bearing mice. Our results suggest that Hemo-
HIM may be a beneficial supplement during cisplatin
chemotherapy by enhancing the anti-tumor efficacy and
reducing the toxicity of cisplatin.
Methods
Animals
Research was approved and conducted according to the
principles enunciated in the 'Animal Care Act', prepared
by the Ministry of Agriculture and Forestry, Republic of
Korea. 8-week-old female C57BL/6 (H-2b) mice were used
(The Orient Inc.; Charles River Technology; Seoul, Korea).
The mice were housed in polycarbonate cages under a spe-
cific pathogen-free condition, and were fed with a stand-
ard animal diet and water ad libitum.
Preparation of HemoHIM
A mixture of 3 edible medicinal herbs, Angelica Radix
(root of Angelica gigas Nakai), Cnidii Rhizoma (rhizome
of Cnidium officinale Makino), and Paeonia Radix (root of
Paeonia japonica Miyabe), was decocted for 4 hours in
boiling water to obtain a total extract (HIM-I). One half of
HIM-I was fractionated into an ethanol-soluble fraction
and into an ethanol-insoluble polysaccharide fraction by
a precipitation in 80% ethanol. HemoHIM was prepared
by adding the ethanol-insoluble polysaccharide fraction
to the other half of HIM-I.
Cell culture
B16F0 (Melanoma cell line; CRL-6322) and YAC-1 (Mol-
ony virus induced leukemia; TIB-160) were purchased from
ATCC (Rockville, MD, USA) and cultured in RPMI 1640
supplemented with 10% fetal bovine serum (FBS, GIBCO
BRL, Grand Island, USA)), 2 × 10-2 M HEPES buffer, 2 × 10-
3 M L-glutamine, 100 U/ml penicillin and 50 μg/ml strep-
tomycin (GIBCO BRL). All cells were grown at 37°C in a
humidified atmosphere containing 5% CO2.BMC Cancer 2009, 9:85 http://www.biomedcentral.com/1471-2407/9/85
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Cisplatin injection and HemoHIM administration in 
tumor-bearing mice model
Mice were divided randomly into three groups (Control,
Cisplatin and Cisplatin+HemoHIM), and each group con-
sisted of twenty mice. B16F0 melanoma (5 × 105 cells/
mouse) was inoculated into subcutaneous femoral left
region of mice at 3 days before an initial injection of cis-
platin. Cisplatin was injected intraperitoneally at 4 mg/kg
body weight (B.W.) on day 0, 7 and 14 (total three injec-
tions). Experimental group was intubated with Hemo-
HIM at a final concentration of 100 mg/kgB.W. by
everyday from day -1 to day 16, while the control group
received only water. The scheme of the administration
procedure is summarized in Fig. 1. On day 17 after initial
injection of cisplatin, all mice of each group were experi-
mented, respectively, to evaluate tumor weight or tumor
size. The tumor size was calculated as follows: tumor size
= ab2/2, where a and b are the larger and smaller diame-
ters, respectively.
Melanoma cell growth assay in vitro
The effect of cisplatin and HemoHIM on the number of
viable melanoma cells was assessed by CCK-8 (WST-8;
Dojindo Lab, Kumamoto, Japan). The principle underly-
ing the cell viability assessment by CCK-8 is based on the
dehydrogenase activity detection in viable cells, similar
with the principle of MTT. Briefly, the melanoma cells
were seeded on to 96-well plates at a density of 7 × 103
cells per well in 100 μl of media. After incubation for 24
hours, cells were treated with various concentration of cis-
platin and with HemoHIM 100 μg/ml for 24 hours. After
incubation, a CCK-8 solution was added to each well.
Cells were incubated at 37°C for two hours and the opti-
cal density was measured using microplate reader (Molec-
ular Devices) at 450 nm (-Ref. 570 nm).
Preparation of lymphocyte in the spleen
Spleens were removed aseptically from the mice and a sin-
gle cell suspension was prepared by mincing the spleen.
The spleen lymphocytes were prepared by a density gradi-
ent centrifugation on a Ficoll-Hypaque solution (Sigma-
Aldrich Co., St. Louis, MO, USA). All the cell suspensions
were maintained in the RPMI 1640 media supplemented
with 10% fetal bovine serum (FBS), 2 × 10-2 M HEPES
buffer, 2 × 10-3 M L-glutamine, 1 × 10-3 M pyruvate, 100
U/ml penicillin, 50 μg/ml streptomycin, 5 × 10-5 M of 2-
mercaptoethanol and 1% nonessential amino acid. All the
supplements were purchased from GIBCO BRL (Grand
Island, USA).
HemoHIM administration in MMC-treated tumor-bearing 
mice model
Firstly, harvested B16F0 melanoma was inactivated by
mitomicin C (MMC) treatment (50 μg/ml, incubation for
40 minutes at 37°C water bath). MMC-treated B16F0
melanoma were inoculated intraperitoneally with 1 × 106
cells/mouse 3 days after an initial administration of
HemoHIM. Experimental group was intubated with
HemoHIM at a final concentration of 100 mg/kgB.W. by
everyday from day -3 to day 4, while the control group was
received only water. Ten days after cancer cell inoculation,
spleen lymphocytes were prepared as effector cells to
measure the activity of NK cells and Tc cells through Cr51-
release assay.
Assay for NK cell and cytotoxic T (Tc) cell mediated cancer 
cell killing activity
YAC-1 tumor targets or B16F0 tumor targets were labeled
with 51Cr-sodium chromate (Amersham Pharmacia Biotech,
Kangnam-ku, Seoul, Korea) at a dose of 40 μCi/106 cells for
60 min to measured NK cell activity or Tc cell activity, respec-
tively. The cells were washed three times in HBSS (Hank's
The experimental schedule used for assessing the efficacy of HemoHIM in melanoma-bearing mice which were injected with  cisplatin Figure 1
The experimental schedule used for assessing the efficacy of HemoHIM in melanoma-bearing mice which were 
injected with cisplatin. B16F0 melanoma cells (5 × 105/mouse) were inoculated into subcutaneous femoral left region of 
mice 3 days before an initial injection of cisplatin. Cisplatin was intraperitoneally injected at 4 mg/kg B.W., and HemoHIM was 
daily given at 100 mg/kg B.W. from day -1 to day 16. On day 17 after initial injection of cisplatin, all mice of each group were 
experimented, respectively, to evaluate various parameters.
Sacrifice
Day -3 0 7 14 17
Cisplatin (4 mg/kg) i.p.
B16F0 s.c.
5 105/mouse
HemoHIM (100 mg/kg/day) p.o.
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Balanced Salt Solution; Sigma-Aldrich Co.) and resuspended
to a final concentration of 2 × 105 cells/ml. Twenty thousand
target cells and 106 or 2 × 106 spleen effector cells were plated
into the wells of a 96-well U bottom plate. The plates were
then incubated at 37°C for 4 hr in humidified air containing
5% CO2. Following a centrifugation at 350 g for 10 min, 100
μl of the supernatant was harvested from each well and
counted for 1 min in a gamma counter (Wallac, Wellesley,
MA, USA). The percent lysis was calculated as follows: % lysis
= {[CPM (experimental) - CPM (spontaneous)]/[CPM
(maximum) - CPM (sponstaneous)]} × 100.
Flow cytometry analysis of NK and Tc cells in spleen 
lymphocytes
The spleen lymphocytes were stained with fluorescent-
labeled antibodies or isotype control antibodies in phos-
phate buffered saline (PBS). After staining for 30 minutes,
the lymphocytes were washed three times with a fresh
FACS media and then analyzed by flow cytometry (Back-
man Coulter, Miami, Florida, USA). A fluorescence histo-
gram of at least 50,000 counts was analyzed in each
sample. The following reagents from BD PharMingen
The inhibition of tumor growth was enhanced by HemoHIM administration in melanoma-bearing mice which were injected  with cisplatin Figure 2
The inhibition of tumor growth was enhanced by HemoHIM administration in melanoma-bearing mice which 
were injected with cisplatin. All mice performed as described in figure 3 were sacrificed at 17 days after initial injection of 
cisplatin. Tumor weight (A) and size (B) were measured. (C) Photographs of melanoma solid tumor taken from all mice of 
each group. There were twenty mice in each group. Data show the Mean ± SD. *p < 0.1 compared with only cisplatin treated 
group.
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Growth inhibition effect of cisplatin and HemoHIM on  melanoma cells in vitro Figure 3
Growth inhibition effect of cisplatin and HemoHIM 
on melanoma cells in vitro. The melanoma cells were 
seeded at a density of 7 × 103 cells per well. After incubation 
for 24 hours, cells were treated with various concentration 
of cisplatin and with HemoHIM 100 μg/ml for 24 hours. After 
incubation, a CCK-8 solution was added to each well for 1 
hour and then the optical density was measured.
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(San Diego, CA, USA) were used: PE-conjugated anti-
NK1.1 and FITC-conjugated anti-CD8.
Condition for a cytokine production in vitro
The spleen lymphocytes (2 × 106 cells/well) obtained
from the mice were stimulated with concanavalin A
(ConA) at 1 μg/ml for 1 or 2 days to measure IL-2 and
IFN-γ level in supernatant.
Antibodies and the enzyme-linked immunosorbent assay 
(ELISA)
For the IL-2, clone JES6-1A12 was used as the capture Ab,
and biotin-labelled JES6-5H4 was the detecting Ab. For
the IFN-γ measurements, clone R4-6A2 was used as the
capture Ab, and biotin-labeled XMG1.2 was the detecting
Ab. All the antibodies as well as the recombinant IFN-γ
and IL-2 were purchased from BD PharMingen (San
Diego, CA, USA). Cytokines were determined by previ-
ously described ELISA method [26].
Histopathological examination of kidney by hematoxylin 
and eosin staining
Kidney from mice of each group on day 17 after initial
injection of cisplatin was removed and fixed in 10% buff-
ered formalin for 2 days. The paraffin-embedded sections
(5 μm thick) were stained with hematoxylin and eosin
(H&E) for histolpathological examination and observed
under light microscope at × 200 magnifications.
Statistical analysis
Data were expressed as mean ± S.D. and a statistical signif-
icance was analyzed by using a Student's t-test. Differences
with a p value of less than 0.05 were taken as significant,
and considerable with a p value of less than 0.1.
Results
HemoHIM enhances the antitumor efficacy of cisplatin in 
tumor-bearing mice
To assess the effect of HemoHIM on tumor growth inhibi-
tion in cisplatin treated B16F0 melanoma-bearing mice,
we used a tumor-bearing mice model that was summa-
rized in Fig. 1. As shown in Fig. 2A and 2B, at 20 days after
melanoma inoculation, the tumor weight and size of the
control group without cisplatin and HemoHIM treatment
were 6.093 g (± 2.28) and 12.6 mm3 (± 5.65), respectively.
However, in the cisplatin-injected group, tumor weight
(2.97 g (± 1.29)) and size (6.3 mm3  (± 2.32)) were
reduced significantly in comparison to the control group.
HemoHIM supplementation with cisplatin resulted in a
further reduction in both the tumor weight (2.22 g (±
1.24)) and size (4.7 mm3 (± 2.93)). Only HemoHIM sup-
plementation without cisplatin showed no reduction in
tumor weight [6.15 g (± 1.238)] when compared with the
control group (Data not shown). This suggests that
HemoHIM itself did not show a reduction effect of tumor
growth. Photographs are shown in Fig. 2C.
HemoHIM enhances the activity of NK and Tc cells rather 
than directly killing cancer cells
The anticancer effect of cisplatin mainly depends on its
DNA-damaging activity, via its direct interaction with
DNA to form DNA adducts [27]. As shown in Fig. 3, cispl-
atin inhibited melanoma cell growth in a dose-dependent
manner, with IC50 at about 15 μg/ml. However, Hemo-
HIM itself did not inhibit melanoma growth in vitro (Data
not shown), nor did it disturb the working of cisplatin in
vitro (Fig. 3).
Because HemoHIM did not directly kill cancer cells, we
thought that the activity of immune cells which were in
charge of tumor surveillance may be enhanced by Hemo-
HIM. We investigated the cancer cell-killing activity of NK
and Tc cells, as they are in charge of innate and adaptive
immunity against tumor, respectively. To investigate the
activity of Tc cell, we used the mice which were immu-
nized with mitomycin C (MMC)-treated melanoma cells.
As shown in Fig. 4A and 4B, HemoHIM administration
enhanced cancer cell-killing activity of NK cells and Tc
cells in MMC-treated melanoma cell-bearing mice (p <
0.05 and p = 0.06, respectively). Also, the proportion of
NK cell in spleen lymphocytes was increased by Hemo-
HIM administration (p < 0.05), but not the proportion of
Tc cells. Specially, these results were important because
NK cells take part in both innate and adaptive immunity,
and are regarded as interfaces between the innate and
adaptive immune systems [28].
The enhanced efficacy of cisplatin with HemoHIM in 
melanoma-bearing mice was due to increasing IL-2 and IFN-
γ secretion and enhancing the activity of NK and Tc cells
As the mechanisms for an enhanced anticancer efficacy of
cisplatin in combination with HemoHIM in melanoma
cell-bearing mice (Fig. 1), we concentrated on the activity
of NK and Tc cells because these cells play an important
role on cancer surveillance. As shown Fig. 5A and 5B, cis-
platin injection alone in melanoma-bearing mice did not
enhance or decrease the activity of NK cells and Tc cells.
However, HemoHIM administration enhanced the activ-
ity of NK cells in melanoma-bearing mice which were
treated with cisplatin (p = 0.1; Fig. 5A). In addition, the
activity of Tc cells was enhanced significantly by Hemo-
HIM administration (p < 0.05; Fig. 5B). These data sug-
gested that the enhanced anticancer efficacy of cisplatin in
combination with HemoHIM administration was due to
the increase in the activity of NK and Tc cells that are in
charge of tumor surveillance.
Macrophages, dendritic cells, NK cells and Tc cells that are
able to recognize, bind and subsequently kill tumor cells,
were activated by cytokines such as IL-2 and IFN-γ. In our
previous study, lymphocytes treated with HemoHIM
alone enhanced the expression of IL-2 and IFN-γ in vitro
(data not shown). Truly, IL-2 and IFN-γ are potent activa-BMC Cancer 2009, 9:85 http://www.biomedcentral.com/1471-2407/9/85
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tors of NK cell and Tc cell effector functions. We therefore
ascertained whether HemoHIM administration enhanced
the production of IL-2 and IFN-γ in melanoma-bearing
mice treated with cisplatin. HemoHIM administration sig-
nificantly enhanced IL-2 (p < 0.001; Fig. 5C) and IFN-γ (p
< 0.05; Fig. 5D) production in melanoma-bearing mice
treated with cisplatin.
HemoHIM decreases the cisplatin-induced nephrotoxicity 
in tumor-bearing mice
Undesirable side effects of cisplatin appear in the kidney
and liver, due to cisplatin accumulation in these organs
[3]. As one of the mechanisms for cisplatin-induced toxic-
ity is the enhanced production of ROS in these organs, we
thought that HemoHIM may have a radical scavenging
activity [20,21], reducing cisplatin-induced damage.
Experimental studies in animals have shown that a mini-
mum dose of cisplatin (5 mg/kg body weight, i.p.) was
sufficient to induce nephrotoxicity in rats [29,30]. In this
study, the cisplatin was injected at 4 mg/kg body weight
three times once weekly. The nephrotoxicity was assessed
using kidneys removed from mice on day 17 after an ini-
tial injection of cisplatin, and the representative result of
each group is shown in Fig. 6. In the histopathological
examination of the kidney, cisplatin destroyed renal tubu-
lar cells (Fig. 6). However HemoHIM administration
reduced the destruction of renal tubular cells by cisplatin.
Discussion
HemoHIM is an herbal composition designed to protect
the self-renewal tissues and to promote the recovery of the
immune system against an oxidative stresses such as an
Effect of HemoHIM on cancer cell killing activity of NK cells and Tc cells Figure 4
Effect of HemoHIM on cancer cell killing activity of NK cells and Tc cells. C57BL/6 mice were orally administrated 
with HemoHIM (100 mg/kg B.W.) and injected with MMC-treated B16F0 melanoma (1 × 106cell/mouse) into peritoneal cavity. 
10 days after cancer cell inoculation, the cancer cell killing activity of NK cells or Tc cells was determined by 51Cr release assay 
as described in Materials and Methods. There were six mice in each group. Data show the Mean ± SD. * p = 0.06 and ** p < 0.05 
compared with mice administrated water.
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irradiation. In this study, we examined the possibility of
HemoHIM both to enhance the anticancer effect of cispl-
atin and to reduce its side effects in melanoma-bearing
mice. In our previous studies, HemoHIM was tested for its
efficacy as a radioprotective agent [20,21]. Also, we inves-
tigated the effect of HemoHIM on a restoration of the
immune functions which had been impaired in aged mice
[31]. Besides, in our previous study, we showed that
HemoHIM accelerated the recovery of immune cells in
mice treated with cyclophosphamide, which is a well-
known anticancer agent [32]. In this study, unlike cispla-
tin, HemoHIM alone did not directly kill the cancer cells.
Nevertheless, our results showed that HemoHIM admin-
istration enhanced antitumor efficacy of cisplatin in
melanoma-bearing mice.
Immune responses that are capable of killing tumor cells
consist of dendritic cells, macrophages, NK cells and Tc
cells. Tc cells may perform a surveillance function by rec-
ognizing and killing potentially malignant cells that
express peptides derived from mutant cellular proteins or
oncogenic viral proteins and presented in association with
class I MHC molecules. NK cells kill many types of tumor
cells, especially cells that have reduced class I MHC
expression and can escape killing by Tc cells [33]. In vitro
studies using cells from humans and several other mam-
malian species, as well as in vivo studies in mice and rats,
have long suggested that tumor cells are recognized as NK
cell targets [34]. Also, NK cells act as regulatory cells to
influence various other cell types, such as dendritic cells,
helper T (Th) cells, Tc cells and B cells [35]. Many studies
for immuno-cancer therapy were focused on enhancing
the activity of NK cells as well as Tc cells against tumor
cells. In our data, cisplatin alone decreased tumor size, but
did not enhance the activity of NK cells and Tc cells (Fig.
5). Also, HemoHIM alone without cisplatin did not
enhance the activity of these cells (data not shown). How-
ever, HemoHIM administration with cisplatin injection
HemoHIM administration promotes immune responses for tumor surveillance in melanoma-bearing mice which were injected  with cisplatin Figure 5
HemoHIM administration promotes immune responses for tumor surveillance in melanoma-bearing mice 
which were injected with cisplatin. All mice performed as described in figure 3 were sacrificed at 17 days after initial injec-
tion of cisplatin. (A)(B) The cancer cell killing activity of NK cells or Tc cells was determined by 51Cr release assay as 
described in Materials and Methods. (C)(D) Spleen lymphocytes were cultured with ConA (1 μg/ml). After 1 or 2 days, IL-2 and 
IFN-γ in culture supernatants were measured by ELISA as described in Materials and Methods. There were twenty one mice in 
each group. The spleens of three mice were pooled. Bars show the means ± SD of the septuple experiments. * p = 0.1, **p < 
0.05 and ***p < 0.001 compared with only cisplatin treated group.
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increases the activity of NK cells and Tc cells in
melanoma-bearing mice (Fig. 5A and 5B), while the
tumor size was decreased by cisplatin. Thus, we suggest
that the mechanism of action of cisplatin and HemoHIM
in tumor-bearing mice differ.
IL-2 and IFN-γ are potent activators of NK cell and Tc cell
effecter functions. For these reasons, cytokine therapies of
malignant tumors using IL-2, IL-12, and IFN-γ have been
investigated extensively in experimental and clinical stud-
ies [34]. It is also well known that IL-2 and IFN-γ promote
tumor-reactive lymphocyte proliferation, cytotoxicity
and, to some extent, cytokine secretion [36-41]. IFN-γ is a
pleiotropic immunoregulatory cytokine that has been
used for clinical treatment of certain tumors [42,43].
However, the clinical application of such cytokines has
been hampered largely due to their undesirable side
effects [44,45]. In our data, HemoHIM administration
with cisplatin injection increased the secretion of IL-2 and
IFN-γ in melanoma-bearing mice.
Although cisplatin is an anticancer drug highly effective
against several cancers, cisplatin is toxic to liver and kid-
ney cells through producing ROS [1-4,30]. However,
many studies to counter nephrotoxicity through the
administration of antioxidants have been performed [8-
10]. As HemoHIM was designed to protect the self-
renewal tissues and to promote a recovery of the immune
system against oxidative stresses [20,21], we thought it
may be able to decrease cisplatin-induced kidney damage.
As expected, HemoHIM administration reduced nephro-
toxicity as seen by tubular cell destruction of kidney.
Based on the overall these results, the possibility of
HemoHIM both to enhance anticancer effect of cisplatin
and to reduce its side effects in melanoma-bearing mice
were ascertained. However, the protective efficacy of
HemoHIM on cisplatin-induce damage in the kidney
needs to be investigated further.
Conclusion
In conclusion, although the manner in which HemoHIM
administration decreases cisplatin-induced kidney dam-
age remains unknown, our results indicate that Hemo-
HIM may be a useful complementary agent during
cisplatin chemotherapy by enhancing the anti-tumor effi-
cacy and reducing the toxicity of cisplatin.
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HemoHIM reduces the cisplatin-induce damage of kidney Figure 6
HemoHIM reduces the cisplatin-induce damage of kidney. Kidney from mice of each group on day 17 after initial injec-
tion of cisplatin was removed and fixed in 10% buffered formalin for 2 days. The paraffin-embedded sections (5 μm thick) were 
stained with hematoxylin and eosin (H&E) for histolpathological examination and observed under light microscope at × 200 
magnifications. The result shown here is representative cortex from each group. (A) Control, cortex (× 200), (B) Cisplatin 
control, cortex (× 200), renal tubule cell destruction (marked by arrows), (C) Cisplatin+HemoHIM, cortex (× 200).
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